DEPDC1

DEPDC1 Full Name

DEP domain containing 1

DEPDC1 Introduction

DEPDC1, short for DEP domain-containing protein 1, is a human gene that encodes a protein primarily studied for its regulatory roles in cell division and its strong association with cancer progression. The protein features a conserved DEP domain (Dishevelled, Egl-10, and Pleckstrin domain), which is typically involved in protein-protein interactions and membrane localization. First identified in the context of embryonic development and tissue homeostasis, DEPDC1 has since garnered significant attention in oncology due to its aberrant overexpression in multiple tumor types, making it a promising biomarker and therapeutic target.The hallmark of DEPDC1 is its N-terminal DEP domain, which facilitates binding to phospholipids and other signaling molecules, allowing the protein to anchor at the plasma membrane or intracellular vesicles. This domain enables DEPDC1 to participate in key signaling cascades, including the NF-κB and Wnt/β-catenin pathways, by acting as a scaffold or adaptor protein. Additionally, the protein contains several phosphorylation sites that modulate its activity and stability in response to cellular cues. Unlike other DEP-containing proteins, DEPDC1 appears to have a specialized role in regulating mitosis, particularly during the G2/M checkpoint, where it influences chromosome segregation and spindle assembly.

Figure1. Structure of DEPDC1.

Expression Patterns and Regulation
In normal adult tissues, DEPDC1 expression is typically low or restricted to proliferative compartments such as the testis, thymus, and fetal organs. However, its transcription is tightly controlled during the cell cycle, peaking in the S and G2 phases, suggesting a role in preparing cells for division. Regulation occurs at both transcriptional and post-translational levels: the gene is repressed by tumor suppressors like p53, while its protein levels are controlled by ubiquitin-proteasome degradation via E3 ligases. Hypoxia and inflammatory cytokines have also been shown to upregulate DEPDC1, linking its expression to stress responses and microenvironmental cues.

Role in Cancer and Disease Pathology
Overexpression of DEPDC1 has been documented in a wide range of malignancies, including hepatocellular carcinoma, breast cancer, lung adenocarcinoma, glioblastoma, and bladder cancer. In these contexts, elevated DEPDC1 promotes uncontrolled proliferation, inhibits apoptosis, and enhances metastatic potential through epithelial-mesenchymal transition (EMT). Clinically, high DEPDC1 levels correlate with poor patient survival, advanced tumor grade, and chemoresistance. Mechanistically, DEPDC1 achieves these effects by activating pro-survival kinases (e.g., AKT) and stabilizing oncogenic transcription factors, while simultaneously suppressing apoptotic mediators like BIM. Consequently, DEPDC1 is being actively investigated as a prognostic indicator and a candidate for targeted therapy.

Alternate Names for DEPDC1

DEPDC1; DEP domain containing 1; DEP domain-containing protein 1A; DEP.8; DEPDC1A; FLJ20354; SDP35; 5830484J08Rik; cell cycle control protein SDP35; DEPDC1-V2;